M. Hernández Porto, T. Delgado, A. Aguirre-Jaime, M. J. Ramos, S. Campos, O. Acosta, Ana Belén Llanos, M. Lecuona
{"title":"Covid-19后肺纤维化风险患者:肺后遗症和体液反应","authors":"M. Hernández Porto, T. Delgado, A. Aguirre-Jaime, M. J. Ramos, S. Campos, O. Acosta, Ana Belén Llanos, M. Lecuona","doi":"10.26502/acbr.50170299","DOIUrl":null,"url":null,"abstract":"Background: The COVID-19 pandemic is one of the major public health problems. The aim of this study is to characterize patients hospitalized for COVID-19 pneumonia at risk of pulmonary fibrosis and to know the amount of protective antibodies and their permanence in these patients. Methods: Follow-up study of the humoral response in hospitalized patients at risk of pulmonary fibrosis post-COVID-19 who were followed up for one year after hospital discharge. Results: The study included 72 patients, 52 of whom had pre-existing chronic comorbidities. COVID-19 clinical severity was rated in 6% as mild, 58% as moderate and 36% as severe. After one year follow-up, forty percent had pulmonary sequelae, the most frequent being mild pulmonary fibrosis. All patients presented RBD IgG, 88% IgA after 8-9 months. The amount of RBD IgG was similar at 4-5 and 8-9 months post-COVID-19. There was no difference in RBD IgG level according to COVID-19 severity ( P = .441, P = .594). Conclusions: The amount of RBD IgG is maintained throughout the convalescent phase and could protect against new reinfections in patients at risk of pulmonary fibrosis Post Covid-19. However, it does not seem to predict the development or not of pulmonary fibrosis.","PeriodicalId":72279,"journal":{"name":"Archives of clinical and biomedical research","volume":"14 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Patients at Risk of Pulmonary Fibrosis Post Covid-19: Pulmonary Sequelae and Humoral Response\",\"authors\":\"M. Hernández Porto, T. Delgado, A. Aguirre-Jaime, M. J. Ramos, S. Campos, O. Acosta, Ana Belén Llanos, M. Lecuona\",\"doi\":\"10.26502/acbr.50170299\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: The COVID-19 pandemic is one of the major public health problems. The aim of this study is to characterize patients hospitalized for COVID-19 pneumonia at risk of pulmonary fibrosis and to know the amount of protective antibodies and their permanence in these patients. Methods: Follow-up study of the humoral response in hospitalized patients at risk of pulmonary fibrosis post-COVID-19 who were followed up for one year after hospital discharge. Results: The study included 72 patients, 52 of whom had pre-existing chronic comorbidities. COVID-19 clinical severity was rated in 6% as mild, 58% as moderate and 36% as severe. After one year follow-up, forty percent had pulmonary sequelae, the most frequent being mild pulmonary fibrosis. All patients presented RBD IgG, 88% IgA after 8-9 months. The amount of RBD IgG was similar at 4-5 and 8-9 months post-COVID-19. There was no difference in RBD IgG level according to COVID-19 severity ( P = .441, P = .594). Conclusions: The amount of RBD IgG is maintained throughout the convalescent phase and could protect against new reinfections in patients at risk of pulmonary fibrosis Post Covid-19. However, it does not seem to predict the development or not of pulmonary fibrosis.\",\"PeriodicalId\":72279,\"journal\":{\"name\":\"Archives of clinical and biomedical research\",\"volume\":\"14 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of clinical and biomedical research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26502/acbr.50170299\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of clinical and biomedical research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26502/acbr.50170299","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Patients at Risk of Pulmonary Fibrosis Post Covid-19: Pulmonary Sequelae and Humoral Response
Background: The COVID-19 pandemic is one of the major public health problems. The aim of this study is to characterize patients hospitalized for COVID-19 pneumonia at risk of pulmonary fibrosis and to know the amount of protective antibodies and their permanence in these patients. Methods: Follow-up study of the humoral response in hospitalized patients at risk of pulmonary fibrosis post-COVID-19 who were followed up for one year after hospital discharge. Results: The study included 72 patients, 52 of whom had pre-existing chronic comorbidities. COVID-19 clinical severity was rated in 6% as mild, 58% as moderate and 36% as severe. After one year follow-up, forty percent had pulmonary sequelae, the most frequent being mild pulmonary fibrosis. All patients presented RBD IgG, 88% IgA after 8-9 months. The amount of RBD IgG was similar at 4-5 and 8-9 months post-COVID-19. There was no difference in RBD IgG level according to COVID-19 severity ( P = .441, P = .594). Conclusions: The amount of RBD IgG is maintained throughout the convalescent phase and could protect against new reinfections in patients at risk of pulmonary fibrosis Post Covid-19. However, it does not seem to predict the development or not of pulmonary fibrosis.